About cognition therapeutics inc - CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
CGTX At a Glance
Cognition Therapeutics, Inc.
2500 Westchester Avenue
Purchase, New York 10577
| Phone | 1-412-481-2210 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -23,487,000.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CGTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.502 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.301 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.01 |
CGTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,677,642.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CGTX Liquidity
| Current Ratio | 3.447 |
| Quick Ratio | 3.447 |
| Cash Ratio | 2.657 |
CGTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -59.745 |
| Return on Equity | -88.595 |
| Return on Total Capital | -67.281 |
| Return on Invested Capital | -87.707 |
CGTX Capital Structure
| Total Debt to Total Equity | 1.862 |
| Total Debt to Total Capital | 1.828 |
| Total Debt to Total Assets | 1.318 |
| Long-Term Debt to Equity | 0.569 |
| Long-Term Debt to Total Capital | 0.559 |